Literature DB >> 10919041

Surgery for mixed hepatocellular and cholangiocellular carcinoma.

T Uenishi1, K Hirohashi, T Shuto, T Yamamoto, S Kubo, H Tanaka, T Ikebe, H Kinoshita.   

Abstract

BACKGROUND/AIMS: Mixed tumors composed of hepatocellular carcinoma and cholangiocellular carcinoma are rare. In this report, the clinicopathologic characteristics and treatment outcome of four patients with mixed hepatocellular and cholangiocellular carcinomas are described.
METHODOLOGY: Of 539 patients with primary liver cancer who underwent hepatic resection in our department over a 17-year period, 4 were diagnosed with mixed hepatocellular and cholangiocellular carcinoma. The clinicopathological features and treatment outcomes of these 4 patients were investigated.
RESULTS: All 4 patients were positive for hepatitis C virus antibody and had hypervascular tumors. Tumor resection was performed for all patients. Three underwent lymph node dissection. At the time of this study, 1 patient was alive without recurrence 12 months after surgery. The other patients died within 28 months of surgery.
CONCLUSIONS: Mixed tumors should be considered in patients with a liver mass and increased serum carcinoembryonic antigen and carbohydrate antigen 19-9 concentrations, a low alpha-fetoprotein concentration, and hypervascularity. The cholangiocellular carcinoma component appears to determine the prognosis.

Entities:  

Mesh:

Year:  2000        PMID: 10919041

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  8 in total

1.  Management of combined hepatocellular-cholangiocarcinoma: a case report and literature review.

Authors:  Ming Chi; Kaidi Mikhitarian; Chanjuan Shi; Laura W Goff
Journal:  Gastrointest Cancer Res       Date:  2012-11

2.  Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy.

Authors:  Thomas J Vogl; Wolfram Schwarz; Katrin Eichler; Kathrin Hochmuth; Renate Hammerstingl; Ursula Jacob; Albert Scheller; Stephan Zangos; Matthias Heller
Journal:  J Cancer Res Clin Oncol       Date:  2006-07-21       Impact factor: 4.553

3.  Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma.

Authors:  Di Tang; Hiroaki Nagano; Masato Nakamura; Hiroshi Wada; Shigeru Marubashi; Atsushi Miyamoto; Yutaka Takeda; Koji Umeshita; Keizo Dono; Morito Monden
Journal:  J Gastrointest Surg       Date:  2006 Jul-Aug       Impact factor: 3.452

4.  Combined hepatocellular and cholangiocellular carcinoma presenting with radiological characteristics of focal nodular hyperplasia.

Authors:  Inneke Willekens; Anne Hoorens; Caroline Geers; Bart Op de Beeck; Frederik Vandenbroucke; Johan de Mey
Journal:  World J Gastroenterol       Date:  2009-08-21       Impact factor: 5.742

5.  Perihilar cholangiocarcinoma arising in hepatitis C virus-related liver cirrhosis with hepatocellular carcinoma.

Authors:  Takahiko Fujii; Yoh Zen; Yasuni Nakanuma
Journal:  J Gastroenterol       Date:  2007-08-24       Impact factor: 7.527

6.  Importance of surgical margin in the outcomes of hepatocholangiocarcinoma.

Authors:  Ka Wing Ma; Kenneth Siu Ho Chok
Journal:  World J Hepatol       Date:  2017-05-08

7.  Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer.

Authors:  T Uenishi; S Kubo; K Hirohashi; H Tanaka; T Shuto; T Yamamoto; S Nishiguchi
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

8.  Clinicopathological features and surgical outcomes of four rare subtypes of primary liver carcinoma.

Authors:  Zhiyu Li; Xiaolong Wu; Xinyu Bi; Yefan Zhang; Zhen Huang; Haizhen Lu; Hong Zhao; Jianjun Zhao; Jianguo Zhou; Muxing Li; Jianming Ying; Jianqiang Cai
Journal:  Chin J Cancer Res       Date:  2018-06       Impact factor: 5.087

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.